慢性胰腺炎的诊断与管理:综述
本文综述慢性胰腺炎的诊断与管理。在美国成人中患病率为42-73/10万。遗传和环境因素共同参与发病,酗酒(每日≥5杯 vs 戒酒/少量饮酒,OR 3.1)和吸烟(>35包年,OR 4.59)与发病相关。诊断基于CT/MRI显示的胰腺钙化、胰管扩张和萎缩,超声内镜可辅助诊断。一线治疗为戒酒戒烟和镇痛(非甾体抗炎药和弱阿片类如曲马多),胰酶和抗氧化剂试验可控制至多50%患者症状;胰管梗阻者可经ERCP或手术引流。
要点
- 慢性胰腺炎诊断基于CT/MRI显示的胰腺钙化、胰管扩张和萎缩,超声内镜可辅助诊断影像正常或可疑的高疑诊患者。
- 一线治疗包括建议戒酒、戒烟和镇痛(非甾体抗炎药和弱阿片类如曲马多)。
- 胰酶和抗氧化剂(多种维生素、硒和甲硫氨酸组合)试验可控制至多50%患者的症状。
- 胰管梗阻(结石、狭窄或两者兼有)者可经ERCP或手术引流(胰管空肠吻合术伴或不伴胰头切除),手术可能对ERCP无效者提供更好的疼痛缓解。
- 长期后遗症包括糖尿病(38%-40%)和外分泌功能不全(30%-48%)。
适用人群与场景
- 美国成人中慢性胰腺炎患病率为42-73/10万。
- 约80%的慢性胰腺炎患者表现为反复或慢性上腹痛。
诊断标准与关键阈值
- 诊断基于CT、MRI或两者显示的胰腺钙化、胰管扩张和萎缩。
- 超声内镜可辅助诊断高疑诊患者,如反复急性胰腺炎发作而影像正常或可疑时。
处置流程与药物剂量
- 一线治疗包括建议戒酒、戒烟和镇痛(非甾体抗炎药和弱阿片类如曲马多)。
- 胰酶和抗氧化剂(多种维生素、硒和甲硫氨酸组合)试验可控制至多50%患者的症状。
- 胰管梗阻(结石、狭窄或两者兼有)者可经ERCP或手术引流(如胰管空肠吻合术伴或不伴胰头切除),手术可能对ERCP无效者提供更好的疼痛缓解。
研究设计与关键结果
- 本综述纳入观察性研究:一项病例对照研究(971名参与者)显示,每日≥5杯饮酒者 vs 戒酒和少量饮酒者的OR为3.1(95%CI 1.87-5.14);>35包年吸烟者的OR为4.59(95%CI 2.91-7.25)。
- 28%-80%的患者被归类为「特发性慢性胰腺炎」,其中高达50%有SPINK1或CFTR基因突变。
- 约1%的慢性胰腺炎患者有遗传性胰腺炎,与PRSS1基因突变相关。
- 长期后遗症包括糖尿病(38%-40%)和外分泌功能不全(30%-48%)。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性
对床旁实践的改变
- 对慢性胰腺炎患者,一线处理为建议戒酒、戒烟和镇痛(非甾体抗炎药和弱阿片类如曲马多)。
- 可试用胰酶和抗氧化剂(多种维生素、硒和甲硫氨酸组合)控制症状。
- 对胰管梗阻(结石、狭窄或两者兼有)且ERCP治疗无效者,手术引流(如胰管空肠吻合术伴或不伴胰头切除)可能提供更好的疼痛缓解。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Chronic pancreatitis (CP) is a chronic inflammatory and fibrotic disease of the pancreas with a prevalence of 42 to 73 per 100 000 adults in the United States.
OBSERVATIONS: Both genetic and environmental factors are thought to contribute to the pathogenesis of CP. Environmental factors associated with CP include alcohol abuse (odds ratio [OR], 3.1; 95% CI, 1.87-5.14) for 5 or more drinks per day vs abstainers and light drinkers as well as smoking (OR, 4.59; 95% CI, 2.91-7.25) for more than 35 pack-years in a case-control study involving 971 participants. Between 28% to 80% of patients are classified as having "idiopathic CP." Up to 50% of these individuals have mutations of the trypsin inhibitor gene (SPINK1) or the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Approximately 1% of people diagnosed with CP may have hereditary pancreatitis, associated with cationic trypsinogen (PRSS1) gene mutations. Approximately 80% of people with CP present with recurrent or chronic upper abdominal pain. Long-term sequelae include diabetes in 38% to 40% and exocrine insufficiency in 30% to 48%. The diagnosis is based on pancreatic calcifications, ductal dilatation, and atrophy visualized by imaging with computed tomography, magnetic resonance imaging, or both. Endoscopic ultrasound can assist in making the diagnosis in patients with a high index of suspicion such as recurrent episodes of acute pancreatitis when imaging is normal or equivocal. The first line of therapy consists of advice to discontinue use of alcohol and smoking and taking analgesic agents (nonsteroidal anti-inflammatory drugs and weak opioids such as tramadol). A trial of pancreatic enzymes and antioxidants (a combination of multivitamins, selenium, and methionine) can control symptoms in up to 50% of patients. Patients with pancreatic ductal obstruction due to stones, stricture, or both may benefit from ductal drainage via endoscopic retrograde cholangiopancreatography (ERCP) or surgical drainage procedures, such as pancreaticojejunostomy with or without pancreatic head resection, which may provide better pain relief among people who do not respond to endoscopic therapy.
CONCLUSIONS AND RELEVANCE: Chronic pancreatitis often results in chronic abdominal pain and is most commonly caused by excessive alcohol use, smoking, or genetic mutations. Treatment consists primarily of alcohol and smoking cessation, pain control, replacement of pancreatic insufficiency, or mechanical drainage of obstructed pancreatic ducts for some patients.
参考来源
- Singh VK, Yadav D, Garg PK, et al. Diagnosis and Management of Chronic Pancreatitis: A Review. JAMA. 2019. PMID: 31860051. doi:10.1001/jama.2019.19411
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。